The Strategic Clinical Innovation Organization (SCIO) method is explicitly designed to help pharmaceutical innovators address their concerns and maneuver around evolving challenges. SCIO identifies time and cost efficiencies and relief from risk management on their journey to market approval. Reach out today to learn more.
– Boston Biotech Clinical Research (BBCR). Strategic Clinical Innovation Experts. Rare Disease, Clinical Trials, Clinical Research, & Biologics. We work with biotech, pharmaceutical, and device companies to develop clinical/regulatory road-maps consisting with simplified clinical programs, streamlined protocols, and cost-effective clinical trials. Our experienced team provides innovative strategies that meet your goals.
An early-phase strategy improves productivity and the path to market approval.
SCIO SM Advantages
Accelerate Patient Recruitment
Reduce Patient Number
Reduce Clinical Development Time
Reduce Trial Monitoring Time
Increase Patient Retention
Facilitate Decision Making
Increase Data Quality
The FDA has been calling for a smarter, more innovative process for market approval, and SCIO SM is the integrative, multidisciplinary approach to deliver it.
Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.